Physician profile
Nathaniel Brooks
NPI 1659728731
$7,985.92
in general payments reported to CMS, 2019-2025
24 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $1,206 · 2023: $1,514 · 2024: $2,592 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,336 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,335.65 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,225.42 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $878.54 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $563.44 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $561.05 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $531.53 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $475.83 | 2021-2025 | Trintellix |
| Lundbeck LLC | $439.17 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $423.62 | 2022-2025 | Fanapt |
| Almatica Pharma LLC | $340.53 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $220.92 | 2025 | Austedo Xr |
| Neurocrine Biosciences, INC. | $204.23 | 2022-2025 | Ingrezza |
| Corium, LLC | $177.52 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $168.72 | 2021-2023 | Aplenzin |
| Janssen Pharmaceuticals, INC | $153.96 | 2022-2023 | Spravato |
| Biogen, INC. | $142.82 | 2023-2025 | Zurzuvae |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $92.31 | 2022-2024 | Jornay Pm |
| Alkermes, INC. | $84.85 | 2021-2023 | Lybalvi |
| Vertical Pharmaceuticals, LLC | $78.50 | 2024-2025 | Relexxii |
| Eisai INC. | $65.42 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $58.16 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $32.80 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $32.25 | 2025 | Cobenfy |
| Livanova USA, INC. | $20.15 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $14.18 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.